Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed AIDS-Related B-Cell Non-Hodgkin's Lymphoma
Public ClinicalTrials.gov record NCT00389818. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II Trial of Doxil, Rituximab, Cyclophosphamide, Vincristine, and Prednisone (DR-COP) in Patients With Newly Diagnosed AIDS-Associated B-Cell Non-Hodgkin's Lymphoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some find cancer cells and help kill them or carry cancer-killing substances to them. Others interfere with the ability of cancer cells to grow and spread. Giving combination chemotherapy together with rituximab may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving combination chemotherapy together with rituximab works in treating patients with newly diagnosed AIDS-related B-cell non-Hodgkin's lymphoma.
Study identification
- NCT ID
- NCT00389818
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 43 participants
Conditions and interventions
Conditions
Interventions
- filgrastim Biological
- pegfilgrastim Biological
- rituximab Biological
- sargramostim Biological
- cyclophosphamide Drug
- pegylated liposomal doxorubicin hydrochloride Drug
- prednisone Drug
- vincristine sulfate Drug
- immunohistochemistry staining method Other
- laboratory biomarker analysis Other
Biological · Drug · Other
Eligibility (public fields only)
- Age range
- 18 Years to 120 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 2007 (Type not available)
- Primary completion
- Sep 2011 (Actual)
- Completion
- Sep 2011 (Actual)
- Last update posted
- Jun 6, 2018
2007 – 2011
United States locations
- U.S. sites
- 14
- U.S. states
- 10
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Rebecca and John Moores UCSD Cancer Center | La Jolla | California | 92093-0658 | — |
| USC/Norris Comprehensive Cancer Center and Hospital | Los Angeles | California | 90089-9181 | — |
| UCLA Clinical AIDS Research and Education (CARE) Center | Los Angeles | California | 90095-1793 | — |
| University of Miami Sylvester Comprehensive Cancer Center - Miami | Miami | Florida | 33136 | — |
| Robert H. Lurie Comprehensive Cancer Center at Northwestern University | Chicago | Illinois | 60611-3013 | — |
| Ochsner Cancer Institute at Ochsner Clinic Foundation | New Orleans | Louisiana | 70121 | — |
| Boston University Cancer Research Center | Boston | Massachusetts | 02118 | — |
| Beth Israel Deaconess Medical Center | Boston | Massachusetts | 02215 | — |
| Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis | St Louis | Missouri | 63110 | — |
| Memorial Sloan-Kettering Cancer Center | New York | New York | 10065 | — |
| Albert Einstein Cancer Center at Albert Einstein College of Medicine | The Bronx | New York | 10461 | — |
| Case Comprehensive Cancer Center | Cleveland | Ohio | 44106-5065 | — |
| Joan Karnell Cancer Center at Pennsylvania Hospital | Philadelphia | Pennsylvania | 19106 | — |
| Virginia Mason Medical Center | Seattle | Washington | 98101 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00389818, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 6, 2018 · Synced Oct 31, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00389818 live on ClinicalTrials.gov.